JP2024534610A - 多環式縮合環誘導体およびその利用 - Google Patents
多環式縮合環誘導体およびその利用 Download PDFInfo
- Publication number
- JP2024534610A JP2024534610A JP2024518761A JP2024518761A JP2024534610A JP 2024534610 A JP2024534610 A JP 2024534610A JP 2024518761 A JP2024518761 A JP 2024518761A JP 2024518761 A JP2024518761 A JP 2024518761A JP 2024534610 A JP2024534610 A JP 2024534610A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- pharma
- stereoisomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/120863 | 2021-09-27 | ||
| CN2021120863 | 2021-09-27 | ||
| CN2022081601 | 2022-03-18 | ||
| CNPCT/CN2022/081601 | 2022-03-18 | ||
| CNPCT/CN2022/102280 | 2022-06-29 | ||
| CN2022102280 | 2022-06-29 | ||
| CN2022120205 | 2022-09-21 | ||
| CNPCT/CN2022/120205 | 2022-09-21 | ||
| PCT/CN2022/121202 WO2023046135A1 (en) | 2021-09-27 | 2022-09-26 | Polycyclic fused ring derivatives and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534610A true JP2024534610A (ja) | 2024-09-20 |
| JP2024534610A5 JP2024534610A5 (cg-RX-API-DMAC7.html) | 2025-09-16 |
Family
ID=85720111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518761A Pending JP2024534610A (ja) | 2021-09-27 | 2022-09-26 | 多環式縮合環誘導体およびその利用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250034166A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4408851A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024534610A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240070619A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118019746A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023046135A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025525406A (ja) * | 2022-07-05 | 2025-08-05 | ファイザー・インク | ピリド[4,3-d]ピリミジン化合物 |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of the KRAS G12C mutant |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| CN119365467A (zh) | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
| KR20250034087A (ko) * | 2022-07-09 | 2025-03-10 | 블로썸힐 테라퓨틱스, 인크. | 질병 치료를 위한 융합 고리 kras 억제제 |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024032704A1 (en) * | 2022-08-11 | 2024-02-15 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024032703A1 (en) * | 2022-08-11 | 2024-02-15 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| AU2023321005A1 (en) * | 2022-08-12 | 2025-03-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tricyclic compounds and medical use thereof |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| KR20250109197A (ko) | 2022-11-21 | 2025-07-16 | 트리라인 바이오사이언시스, 인크. | 스피로환식 디하이드로피라노피리미딘 KRas 억제제 |
| TW202440594A (zh) * | 2022-12-07 | 2024-10-16 | 大陸商北京加科思新藥研發有限公司 | 稠環化合物及其用途 |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| WO2024178304A1 (en) * | 2023-02-24 | 2024-08-29 | Alterome Therapeutics, Inc. | Kras modulators |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| CR20250413A (es) * | 2023-04-05 | 2025-11-06 | Pfizer | Compuestos de pirido[4,3–d]pirimidina |
| WO2024208305A1 (zh) * | 2023-04-07 | 2024-10-10 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| WO2024213979A1 (en) * | 2023-04-10 | 2024-10-17 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024215754A1 (en) * | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121194980A (zh) * | 2023-05-16 | 2025-12-23 | 和记黄埔医药(上海)有限公司 | 三环类化合物及其用途 |
| JP2026524477A (ja) * | 2023-06-30 | 2026-07-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Krasの分解のためのヘテロ二官能性化合物 |
| WO2025006967A1 (en) | 2023-06-30 | 2025-01-02 | Bristol-Myers Squibb Company | Kras inhibitors |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| KR20260054710A (ko) | 2023-08-17 | 2026-04-22 | 트리라인 바이오사이언시스, 인크. | 스피로시클릭 디히드로피라노피리미딘 KRas 저해제 |
| WO2025049619A1 (en) | 2023-08-29 | 2025-03-06 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025064848A1 (en) | 2023-09-21 | 2025-03-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyridine kras inhibitors |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20260096846A (ko) * | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
| CN117700374B (zh) * | 2023-12-25 | 2026-06-26 | 吉尔多肽生物制药(大连市)有限公司 | 手性高吗啉-5-甲酸及其芴甲氧羰基衍生物的制备方法 |
| WO2025148868A1 (zh) * | 2024-01-08 | 2025-07-17 | 泰励生物科技(上海)有限公司 | 一种抗体偶联药物及其用途 |
| WO2025168072A1 (en) * | 2024-02-08 | 2025-08-14 | Beigene (Suzhou) Co., Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| TW202615038A (zh) | 2024-08-07 | 2026-04-16 | 美商太斯萊特醫藥美國有限責任公司 | 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物 |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020519589A (ja) * | 2017-05-11 | 2020-07-02 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | G12c変異型rasタンパク質を阻害するヘテロアリール化合物 |
| WO2022106447A1 (de) * | 2020-11-23 | 2022-05-27 | Valeo Schalter Und Sensoren Gmbh | Aktives sensorsystem und objekterkennung |
| WO2022173678A1 (en) * | 2021-02-09 | 2022-08-18 | Genentech, Inc. | Tetracyclic oxazepine compounds and uses thereof |
| WO2022194245A1 (zh) * | 2021-03-17 | 2022-09-22 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| WO2022268051A1 (zh) * | 2021-06-21 | 2022-12-29 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| WO2023274383A1 (zh) * | 2021-07-02 | 2023-01-05 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| WO2023030385A1 (zh) * | 2021-08-31 | 2023-03-09 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962453A (en) * | 1995-08-08 | 1999-10-05 | Nippon Shinyaku Co. Ltd. | Triazine derivative and medicine |
| CN101203511A (zh) * | 2005-06-23 | 2008-06-18 | 阿斯利康(瑞典)有限公司 | 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物 |
| CN102875556B (zh) * | 2011-07-12 | 2016-03-30 | 天津药明康德新药开发有限公司 | (4s)-1-取代-2,5-二氮杂双环[2,2,1]庚烷衍生物及制备方法 |
| US9181288B2 (en) * | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| IL290276B2 (en) * | 2019-08-02 | 2026-05-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Tetracyclic compounds, method for their preparation and use |
| CN112390818B (zh) * | 2019-08-12 | 2023-08-22 | 劲方医药科技(上海)有限公司 | 取代的杂芳环并二氢嘧啶酮衍生物,其制法与医药上的用途 |
| CN114980976A (zh) * | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| WO2022206723A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
-
2022
- 2022-09-26 CN CN202280065503.XA patent/CN118019746A/zh active Pending
- 2022-09-26 EP EP22872179.1A patent/EP4408851A4/en active Pending
- 2022-09-26 JP JP2024518761A patent/JP2024534610A/ja active Pending
- 2022-09-26 KR KR1020247013592A patent/KR20240070619A/ko active Pending
- 2022-09-26 US US18/695,384 patent/US20250034166A1/en active Pending
- 2022-09-26 WO PCT/CN2022/121202 patent/WO2023046135A1/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020519589A (ja) * | 2017-05-11 | 2020-07-02 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | G12c変異型rasタンパク質を阻害するヘテロアリール化合物 |
| WO2022106447A1 (de) * | 2020-11-23 | 2022-05-27 | Valeo Schalter Und Sensoren Gmbh | Aktives sensorsystem und objekterkennung |
| WO2022173678A1 (en) * | 2021-02-09 | 2022-08-18 | Genentech, Inc. | Tetracyclic oxazepine compounds and uses thereof |
| WO2022194245A1 (zh) * | 2021-03-17 | 2022-09-22 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| WO2022268051A1 (zh) * | 2021-06-21 | 2022-12-29 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| WO2023274383A1 (zh) * | 2021-07-02 | 2023-01-05 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| WO2023030385A1 (zh) * | 2021-08-31 | 2023-03-09 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025525406A (ja) * | 2022-07-05 | 2025-08-05 | ファイザー・インク | ピリド[4,3-d]ピリミジン化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250034166A1 (en) | 2025-01-30 |
| CN118019746A (zh) | 2024-05-10 |
| EP4408851A4 (en) | 2025-09-17 |
| EP4408851A1 (en) | 2024-08-07 |
| WO2023046135A1 (en) | 2023-03-30 |
| KR20240070619A (ko) | 2024-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240070619A (ko) | 폴리사이클릭 융합 고리 유도체 및 이의 용도 | |
| CN117858878A (zh) | N-环丙基吡啶并[4,3-d]嘧啶-4-胺衍生物及其用途 | |
| AU2019320945B2 (en) | Fused ring compounds | |
| CN118139855A (zh) | 1,4-氧杂氮杂环庚烷衍生物及其用途 | |
| JP2023521698A (ja) | Krasの標的化分解のための化合物及び方法 | |
| WO2023020523A1 (en) | Bicyclic derivatives and use thereof | |
| JP2025515139A (ja) | Kras g12dタンパク質分解標的化キメラ | |
| KR20250070059A (ko) | 신규한 테트라헤테로사이클 화합물 | |
| CN111630046B (zh) | 喹唑啉衍生物及其应用 | |
| JP2023554506A (ja) | Fgfr阻害剤化合物及びその使用 | |
| CN120322440A (zh) | 稠环化合物及其应用 | |
| CA3085561A1 (en) | Cyclohexyl acid triazole azines as lpa antagonists | |
| EP4393916A1 (en) | Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof | |
| KR20190101406A (ko) | Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법 | |
| JP2018524367A (ja) | 癌の処置のためのdub阻害剤としてのシアノピロリジン | |
| TW202237597A (zh) | 新型egfr降解劑 | |
| CN110698481A (zh) | 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物 | |
| CN106687446A (zh) | 作为t790m/wt‑egfr的选择性和不可逆的激酶抑制剂的5‑氨基‑4‑氨甲酰基‑吡唑化合物及其用途 | |
| AU2016287335A1 (en) | TBK/IKKepsilon inhibitor compounds and uses thereof | |
| CN116783183B (zh) | 用于治疗贫血和癌症的vhl抑制剂 | |
| JP2018516970A (ja) | ムスカリンm2受容体の正のアロステリックモジュレーター | |
| CN114907341A (zh) | 吡啶并嘧啶酮类衍生物及其制备方法和用途 | |
| CN118103370A (zh) | 作为erbb2抑制剂的稠合四环喹唑啉衍生物 | |
| CN120112518A (zh) | 用于治疗癌症的化合物 | |
| CN116969923B (zh) | 杂芳基氨基化合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250905 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250905 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260519 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260529 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260804 |